Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-06-28
2005-06-28
Criares, Theodore (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S336000
Reexamination Certificate
active
06911479
ABSTRACT:
Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4761501 (1988-08-01), Husbands et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5788986 (1998-08-01), Dodman
patent: 0 112 669 (1984-07-01), None
patent: 0 654 264 (1995-05-01), None
patent: 2 227 743 (1990-08-01), None
patent: WO 94/00047 (1994-01-01), None
patent: 94/00114 (1994-01-01), None
patent: WO 94/00114 (1994-01-01), None
patent: 94/00047 (1994-06-01), None
Taft et al., Drug Metabolism and Disposition, 25(10):1215-1218 (1997).
Moyer et al.,In Vivo Antidepressant Profiles of the Novel Bicyclic Compounds Wy-45,030 and Wy-45,881, Abstracts Society for Neuroscience, Oct. 1984, p. 261.
Haskins et al.,DMI, Wy-45,030, Wy-45,881 and Ciramadol Inhibit Locus Coeruleus Neuronal Activity, European Journal of Pharmacology, 115(1985), pp. 139-146.
Muth et al.,Antidepressant Biochemical Profile of the Novel Bicyclic Compounds Wy-45,030, an Ethyl Cyclohexanol Derivative, Biochemical Pharmacology, vol. 35, No. 24, 1986, pp. 4493-4497.
Pento,Drugs of the Future, vol. 13, No. 9, 1988, pp. 839-840.
Yardley et al.,2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity, J. Med. Chem. 1990, vol. 33, pp. 2899-2905.
Muth et al.,Biochemical, Neurophysiologial, and Behavioral Effects of Wy-45,233 and Other Identified Metabolites of the Antidepressant Venlafaxine, Drug Development Research23:191-199, 1991.
Klamerus et al.,Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite, J. Clin. Pharmacol., 1992, 32:716-724.
Howell et al.,Pharmacokinetics of Venlafaxine and O-desmethylvenlafaxine in Laboratory Animals, Xenobiotica, vol. 24, No. 4, 1994, pp. 315-327.
von Moltke et al.,Venlafaxine and Metabolites are Very Weak Inhibitors of Human Cytochrome P450-3A Isoforms, Biol. Psychiatry 1997, 41:377-380.
Sinclair et al.,The Tolerability of Venlafaxine, Rev. Contemp. Pharmacother. 1998, 9:333-344.
Physicians's Desk Reference, 53rdEdition, 1999, pp. 3293-3302.
Askew,A Simple Screening Procedure for Imipramine-Like Antidepressant Agents, Life Sciences No. 10, Sep. 1963, pp. 725-730.
Steiner et al.,Radioimmunoassay for Cyclic Nucleotides, The Journal of Biological Chemistry, vol. 247, No. 4, Feb. 25, 1972, pp. 1106-1113.
Wilen et al.,Strategies in Optical Resolutions, Tetrahedron, vol. 33, 1977, pp. 2725 to 2736.
Moyer et al.,Subsensitivity of the Beta-Adrenergic Receptor-Linked Adenylate Cyclase System of Rat Pineal Gland Following Repeated Treatment with Desmethylimipramine and Nialamide,Molecular Pharmacology, 19:187-193, 1981.
Wood et al.,The Rapid Preparation of Synaptosomes, Using a Vertical Rotor, Journal of Neurochemistry, vol. 37, No. 3, Sep. 1981, pp. 795-797.
Castello, R.A., and Mattocks, A.M.,J. Phram. Sci.51(2):106-108 (1962).
Handbook of Pharmaceutical Excipients, 2nded., Wade and Willer eds., pp. 257-259 (1994).
Howell, S. R., et al.,Xenobiotical24(4):315-327 (1994).
Klamerus, K.J., et al.,J. Clin. Pharmacol., 32:716-724 (1992).
Muth, E.A., et al.,Drug Develop. Res., 23:191-199 (1991).
Pento, J.T.,Drugs of the Future, 13(9):839-840 (1988).
Physicians' Desk Referencepp. 3293-3302 (53rded., 1999).
Remingtons: The Practice of The Science and Pharmacy, 19thed., Gennaro, ed., p. 1625 (1995).
Rudaz, S., et al.,Chromatographia, vol. 50, No. 5/6, 369-372(1999).
Sinclair, J., et al.,Rev. Contemp. Pharmacother., 9:333-334 (1988).
Yardley., J.P., et al.J. Med. Chem.I33:2899-2905 (1990).
von Moltke, L.L., et al.,Biol. Psychiatry, 41:377-380 (1997).
Wang, C. Paul, et al.,Chirality, 4(2), 84-90 (1992).
Bhongle Nandkumar N.
Jerussi Thomas P
Senanayake Chrisantha H
Criares Theodore
Jones Day
Sepracor Inc.
LandOfFree
Methods of treating and preventing pain, anxiety, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating and preventing pain, anxiety, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating and preventing pain, anxiety, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505550